Sorafenib is a drug approved for the treatment of hepatocellular carcinoma (liver cancer). It works by targeting several proteins involved in cancer growth. However, despite this treatment, the cancer often comes back or spreads. Doctors are therefore seeking more effective therapies for liver cancer.
In this study, researchers want to find the highest dose of the investigational drug dalantercept that can be given with sorafenib in patients with hepatocellular carcinoma that has continued to grow despite prior therapy or has spread. Dalantercept is designed to inhibit tumor growth by blocking the development of the blood vessels that tumors need to grow and spread.
Sorafenib is taken orally (by mouth), while dalantercept is given as an injection under the skin.